By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 144.86 |
Change Today | $ -3.98 |
% Change | -2.67 % |
52 Week High | $201.44 |
52 Week Low | $118.84 |
Volume | 1,810,709 |
Shares Issued | 145.80m |
Market Cap | $21,121m |
Beta | 0.00 |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 6 |
Neutral | 20 |
Sell | 1 |
Strong Sell | 0 |
Total | 34 |
Time | Volume / Share Price |
16:00 | 167,563 @ $144.86 |
15:59 | 1,025 @ $144.85 |
15:59 | 100 @ $144.86 |
15:59 | 100 @ $144.89 |
15:59 | 100 @ $144.93 |
You are here: research